- 01Named for the pineal gland vs shown in the pineal gland
Pinealon's name promises a pineal and sleep effect, but the originating lab's own pineal-tissue study found pinealon did not stimulate pineal cells, and no study has measured melatonin or sleep after pinealon. Its evidence is about brain cells in dishes and preclinical models.
- 02Given to people vs tested in a trial
Two small Russian reports gave pinealon to people, but without a placebo group or blinding, so they can't show whether pinealon helped or harmed; one recorded lower blood stem cells.
Pinealon is named after the pineal gland, the pea-sized gland in the brain that makes melatonin, yet the one study that put pinealon on pineal tissue found it did not stimulate the pineal cells 3. That gap between the name and the data runs through the whole pinealon story: a lab-made peptide sold for sleep, memory and brain ageing, backed by cell-dish work, preclinical studies and two small Russian reports in people, almost all from one St Petersburg research network 1.
| Question | Short answer |
|---|---|
| What it is | A synthetic tripeptide, Glu-Asp-Arg (EDR) |
| Formula and weight | C15H26N6O8, 418.4 g/mol (PubChem CID 10273502) |
| Who made it | Vladimir Khavinson's Institute of Bioregulation and Gerontology, St Petersburg |
| What it is sold for | Memory, sleep, mood and brain ageing |
| Best human evidence | Two small uncontrolled Russian reports (2012, 2015) |
| Approval | None in the US, UK or EU; sold in Russia as a supplement |
| Sport | Prohibited at all times under WADA class S0 |
What is pinealon?
Pinealon is a peptide, meaning a short chain of amino acids, the same building blocks that make up proteins. Pinealon has three of them: glutamic acid, aspartic acid and arginine, written Glu-Asp-Arg or by their one-letter codes, EDR. The molecule's formula is C15H26N6O8 and its weight is 418.4 g/mol, listed in the US National Library of Medicine's PubChem database as compound 10273502. Several popular guides link a different PubChem entry that belongs to an unrelated chemical, so check the number if you look it up.
Pinealon comes out of a programme run by Vladimir Khavinson at the Institute of Bioregulation and Gerontology in St Petersburg. Khavinson's group calls these molecules "peptide bioregulators" or "cytogens": short peptides that, in the group's theory, carry tissue-specific signals that tune gene activity and slow ageing 1. The theory and most of the evidence for it come from that one programme 1. In Russia pinealon is sold as a cytogen dietary supplement. Elsewhere it appears online as "research use only" powder in vials, as capsules and as nasal sprays.
Does pinealon work on the pineal gland, sleep or melatonin?
No published study shows pinealon acting on the pineal gland, and none has measured melatonin after pinealon. In 2011 the Khavinson group grew slices of pineal gland in culture and added several of its short peptides. Epitalon (Ala-Glu-Asp-Gly) made the pineal cells, called pinealocytes, multiply and step up their secretory activity. Pinealon did not, and none of the peptides changed AIF, a marker of programmed cell death 3. That is the originating lab's own result.
The closest thing to a mood or sleep signal is a 2014 dish study from the same group, in which EDR raised serotonin expression in ageing cultures of brain cortex cells (Khavinson and colleagues, Bulletin of Experimental Biology and Medicine). Serotonin is a brain messenger that the body also uses to make melatonin. The proposed link to the serotonin-making gene came from computer modelling. Nobody has checked serotonin, melatonin or sleep in a living person taking pinealon. For what does have evidence on light, timing and sleep, see how light sets your sleep clock.
How pinealon is supposed to work
The Khavinson group's explanation is that very short peptides slip into the cell nucleus, sit on particular stretches of DNA and nudge nearby genes on or off 1. Each step of that chain has been tested in a different, increasingly indirect way, and the final step, a change in a person's brain, has never been tested.
The proposed route from peptide to brain effect, and where the evidence stops
The group also describes pinealon as an antioxidant. Oxidative stress is damage from reactive oxygen species, unstable molecules that cells make as a by-product of using oxygen. In a 2011 dish study, pinealon limited the build-up of reactive oxygen species in a dose-dependent way and cut necrotic cell death in three cell types, including nerve cells from the cerebellum 2. That is a dish result. Many substances quench reactive oxygen species in a dish and do nothing measurable in a person.
What the studies found in cells and preclinical models
The table lists the pinealon studies that sellers lean on, with what each one reported and the limit that matters most. Read the last column first.
| Year | Model | What they reported | What it can't tell you |
|---|---|---|---|
| 2011 | Nerve and immune cells in a dish | Less reactive oxygen species build-up and less necrotic cell death, dose-dependent 2 | Whether anything similar happens in a body |
| 2011 | Pineal gland tissue in culture | Pinealon had no effect on pineal cells; epitalon stimulated them 3 | Nothing in favour of pinealon for sleep |
| 2011 to 2015 | Older preclinical models with blocked neck arteries or low oxygen, often given alongside Cortexin | Better survival and brain-cell markers (Mendzheritsky and colleagues) | Pinealon's own effect, since it was often paired with another product |
| 2012 | Pregnant preclinical models with high homocysteine from diet | Offspring learned a maze better and their nerve cells resisted oxidative stress (Arutjunyan and colleagues) | Anything about adults or about people |
| 2017 | Nerve cells in a dish exposed to amyloid, a model of Alzheimer's | EDR at 200 ng/ml raised mushroom spines by 71%, back to normal levels 4 | Whether memory changes in any living brain; the paper carries a 2017 erratum |
| 2021 | 5xFAD preclinical Alzheimer's model | EDR and the related peptide KED prevented loss of nerve-cell spines 5 | Human benefit; the paper also carries a 2025 erratum |
| 2024 | Human nerve cells grown from other cell types in a dish | Spine and marker changes from the same network | Effects in a person |
Mushroom spines are the large, stable bumps on nerve-cell branches where connections form; losing them tracks with memory loss in Alzheimer's models. A 71% rise at 200 ng/ml in a dish is a real laboratory signal 4. That dish result tells you nothing about the right amount for a person, how long an effect would last, or whether a swallowed peptide would reach those cells.
Has pinealon been tested in people?
Pinealon has been given to people in two small Russian reports, and neither is a controlled trial. Some guides say no human data exist at all; the two reports below are indexed in PubMed, published in Russian in the journal Advances in Gerontology.
The first, from 2012, studied 150 long-haul lorry drivers and 150 metalworkers. The authors reported that cytogen peptides improved psycho-emotional scores, and that the best result came from combining pinealon with vesugen, another Khavinson tripeptide sold for blood vessels 7. The abstract describes no placebo group and no blinding, and the combination makes pinealon's own share impossible to separate.
The second, from 2015, gave pinealon or vesugen to 32 adults aged 41 to 83 who had several chronic illnesses and organic brain syndrome (brain-related problems with thinking and mood) in remission. The authors reported slower markers of "biological age". They also reported prooxidant activity, meaning a push toward oxidative stress, the opposite of the antioxidant effect pinealon is sold for. And they found lower CD34+ cells, the blood stem cells in bone marrow that make new blood cells 6. Vesugen did better than pinealon in the same report 6. With 32 people and no placebo arm, neither the benefit nor the harm can be pinned on the peptide, but the CD34+ finding is the only human safety signal on record.
Who did the research, and why that matters
Nearly every pinealon paper traces back to the Khavinson institute and labs that work with it: the Mendzheritsky group on blocked-artery models, the Arutjunyan and Kozina group on oxidative stress, and the Linkova and Kraskovskaya group on nerve-cell spines 1 5. Much of the work appears in Russian in Advances in Gerontology. As of November 2026, no group outside that network has published a replication of a pinealon finding.
A literature from one source can still be right, but it carries more risk. The same assumptions, methods and incentives repeat from paper to paper, and errors are less likely to be caught. The 2021 Alzheimer's-model paper already carries a published erratum 5. Until an independent lab repeats the key results, treat each pinealon finding as a single-lab claim. The same pattern shows up across peptides sold online without human trials, such as SLU-PP-332 and dihexa.
Pinealon vs epitalon
Pinealon and epitalon come from the same programme and are often sold side by side, so they get confused. Epitalon is a four-amino-acid copy of epithalamin, an extract made from pineal glands; pinealon is a different, shorter peptide 1.
| Pinealon | Epitalon | |
|---|---|---|
| Sequence | Glu-Asp-Arg (EDR), 3 amino acids | Ala-Glu-Asp-Gly (AEDG), 4 amino acids |
| Origin | Designed by the Khavinson group | Synthetic copy of epithalamin, a pineal extract 1 |
| Main claim | Protects brain cells, lowers oxidative stress | Lengthens telomeres, extends lifespan |
| Pineal-tissue result | Did not stimulate pineal cells 3 | Stimulated pineal cell growth and secretion 3 |
| Human evidence | Two small uncontrolled Russian reports 6 7 | Small Russian studies from the same network |
| Approval | Not approved in the US, UK or EU | Not approved in the US, UK or EU |
If the reason for looking at pinealon is the pineal gland, the lab's own data point to epitalon, and epitalon still has no placebo-controlled trial behind it. Both peptides share the same limits: one research network, no independent replication and no regulator's approval.
Pinealon dosage: capsules, nasal sprays and injections
No human dose of pinealon has been tested for safety or effect, so this page gives none. The amounts in the studies do not translate into a capsule or a spray. The 2021 Alzheimer's-model study injected the related tripeptide KED into the abdominal cavity at 400 µg/kg every day from 2 to 4 months of age 5, and the 2017 work used 200 ng/ml in a dish 4. An injection into the body cavity of a small preclinical model and a concentration in a culture dish say nothing about how much of a swallowed capsule reaches a human brain.
Swallowing is the biggest unknown. Stomach acid and gut enzymes break most peptides into single amino acids, and nobody has measured whether EDR survives that trip intact. Glutamic acid, aspartic acid and arginine are ordinary amino acids found in any protein-containing meal. Nasal sprays have no published absorption data for pinealon either. Vendor labels cannot be checked: when Belgian authorities analysed seized peptide products, they found problems with identity and purity, so the vial or capsule may not hold what the label says 8.
Side effects and safety
No Phase 1 study (the first, small safety study in healthy volunteers) has been run on pinealon, and there are no human data on how the body absorbs, spreads or clears it. The side-effect list on seller websites is therefore guesswork. The only human safety signal comes from the 2015 Russian report, which recorded prooxidant activity and lower CD34+ blood stem cells 6. The other unmeasured risk sits in the product: unlicensed peptides can be mislabelled, underdosed, contaminated or a different molecule altogether 8.
These groups have particular reasons for caution, and reasons to discuss any peptide with their doctor first:
- Anyone pregnant or breastfeeding: there are no data at all, and the only pregnancy work is preclinical.
- Anyone with a history of cancer: the 2011 dish study reported that pinealon activated proliferative processes, meaning cell growth 2.
- Anyone on medicines that act on serotonin, such as SSRI antidepressants or triptans: the serotonin link is theoretical, and no interaction study exists.
- Anyone with a blood disorder or low blood counts, given the 2015 CD34+ finding 6.
- Anyone in tested sport: pinealon is prohibited at all times.
Is pinealon legal?
In the US, pinealon is not an FDA-approved drug and is not on the FDA's lists of bulk substances that compounding pharmacies may use, so a US pharmacy has no recognised route to make it on prescription. It is sold online labelled "research use only" or "not for human consumption", a label that keeps it out of the drug and supplement rules and also means no one has checked its contents. In Russia it is sold as a cytogen dietary supplement. In the UK and EU it is unlicensed.
In sport, pinealon falls under the World Anti-Doping Agency's S0 class of non-approved substances, which is banned in and out of competition. The rule reads:
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.World Anti-Doping Agency, The 2026 Prohibited List, section S0
Other peptides sold online face the same rule, including BPC-157 and humanin.
Poor sleep or slipping memory? What to check first
Most people searching for pinealon want sharper memory, steadier mood or better sleep. Several common causes of those problems show up on ordinary blood tests, and each has human evidence behind it. Low vitamin B12 can cause memory trouble and numbness. An underactive thyroid slows thinking and saps energy. Raised homocysteine, an amino acid that builds up when B12 or folate run short, is linked to cognitive decline, the same marker the 2012 preclinical pinealon study raised in pregnant models. High blood sugar over months, measured by HbA1c, is tied to poorer memory. Sleep length and timing, mood and medicines are the other usual suspects; see brain fog and can't sleep for the full lists.
Markers worth reading first

CalculatorSleep calculatorWorks out bed and wake times around full sleep cycles, a first step before blaming the pineal gland.Work it out If you want a supplement with people, not dishes, behind it, a few have small human trials. None is proven, and each is worth raising with your doctor. More options, graded by evidence, are on supplements for brain health.
Compounds to compare
When to get help now
Memory and sleep problems usually have ordinary causes, but some signs need care quickly.
- Sudden confusion, trouble speaking or slurred speech: call 911.
- Sudden weakness or numbness on one side of the body, or a drooping face: call 911.
- Sudden severe headache or a seizure: call 911.
- Memory loss that is new, getting worse, or noticed by family: see a doctor within days to weeks.
- Poor sleep lasting more than a few weeks, or loud snoring with daytime sleepiness: see a doctor.
- Low mood, loss of interest or thoughts of self-harm alongside poor sleep: see a doctor promptly, or call or text 988.
LifeFrom can't examine you or assess a symptom. If something feels seriously wrong, trust that and get care rather than waiting on a test.
Citations
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology, 2010;11:139-149.
- Khavinson V et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research, 2011;14(5):535-541.
- Khavinson VKh et al. Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture. Bulletin of Experimental Biology and Medicine, 2011;152(1):138-141.
- Kraskovskaya NA et al. Tripeptides restore the number of neuronal spines under conditions of in vitro modeled Alzheimer's disease. Bulletin of Experimental Biology and Medicine, 2017;163(4):550-553.
- Khavinson V et al. Neuroprotective effects of tripeptides, epigenetic regulators in mouse model of Alzheimer's disease. Pharmaceuticals (Basel), 2021;14(6):515.
- Meshchaninov VN et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Advances in Gerontology, 2015;28(1):62-67 (in Russian).
- Bashkireva AS, Artamonova VG. The peptide correction of neurotic disorders among professional truck-drivers. Advances in Gerontology, 2012;25(4):718-728 (in Russian).
- Vanhee C et al. Analysis of illegal peptide biopharmaceuticals frequently encountered by controlling agencies. Talanta, 2015;142:1-10.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.









